Table 2.
Concomitant medication.
| All Patients (n = 79) |
Patients with ATTR (n = 65) |
Patients with AL (n = 14) |
|
|---|---|---|---|
| Loop diuretic, n (%) | 62 (78.5) | 53 (81.5) | 9 (64.3) |
| ACE inhibitor/AT1 antagonist, n (%) | 45 (57.0) | 32 (52.3) | 11 (78.6) |
| Thiazide diuretic, n (%) | 3 (3.8) | 3 (4.6) | 0 (0) |
| Sacubitril/valsartan, n (%) | 9 (11.4) | 7 (10.8) | 2 (14.3) |
| Betablocker, n (%) | 41 (51.9) | 35 (53.8) | 6 (42.9) |
| Mineralocorticoid receptor antagonist, n (%) | 26 (32.9) | 25 (38.5) | 1 (7.1) |
| Cardiac glycoside, n (%) | 2 (2.5) | 2 (3.1) | 0 (0) |
| Amiodarone, n (%) | 7 (8.9) | 7 (10.8) | 0 (0) |
| Tafamidis, n (%) | n/a | 60 (92.3) | n/a |
ACE: angiotensin-converting enzyme. AT1: angiotensin II receptor subtype 1. N/a: Not applicable.